Risk factor
Very high price volatility
Profitability factor
Very low or no dividends
About
Antengene Corporation Limited, a biopharmaceutical firm, is dedicated to developing advanced oncology treatments primarily within the Chinese market. Its active clinical development pipeline includes several innovative compounds. Among these, ATG-016, a next-generation XPO1 inhibitor, is currently undergoing Phase I/II clinical trials for individuals with solid tumors. ATG-527 (Verdinexor) has successfully completed its Phase I evaluation for chronic human viral infections. The company is also advancing ATG-019, a dual PAK4/NAMPT inhibitor targeting non-Hodgkin's lymphoma and advanced solid tumors, and ATG-017, an ERK1/2 inhibitor designed for treating advanced solid tumors and hematologic malignancies. Additionally, ATG-010 (selinexor) is a SINE compound that modulates XPO1. ATG-101, a bispecific PD-L1/4-1BB antibody, is in Phase I studies for patients with metastatic/advanced solid tumors and B-cell non-Hodgkin's lymphoma. Completing its clinical-stage assets is ATG-008 (onatasertib), an orally delivered mTOR kinase inhibitor aimed at solid tumors exhibiting specific genetic alterations like NFE2L2, STK11, and RICTOR. In its earlier, pre-clinical research phase, Antengene is exploring ATG-037, a CD73 inhibitor for advanced or metastatic solid tumors; ATG-018, an ATR inhibitor; ATG-022, a Claudin 18.2 antibody-drug conjugate; ATG-031, a CD24 antibody; ATG-027, a B7H3/PD-L1 bispecific antibody; ATG-032, a LILRB antibody; and ATG-041, an Axl-Mer inhibitor. Founded in 2016, the company maintains its headquarters in Shanghai, China.
Company Valuation
Based on key historical and expected multiples, the stock is fairly valued relative to its peers. Specifically, the stock is 'cheap' on P/E.
Target Price
The average target price of 6996.HK is 5.06 and suggests 12.7% upside potential. Usually, this means a HOLD recommendation among investment firms. This neutral recommenda